Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 64 | 2019 | 397 | 9.800 |
Why?
|
| Anti-Asthmatic Agents | 11 | 2017 | 71 | 2.280 |
Why?
|
| Phenotype | 22 | 2019 | 631 | 2.040 |
Why?
|
| Severity of Illness Index | 22 | 2019 | 864 | 1.760 |
Why?
|
| Adrenal Cortex Hormones | 12 | 2019 | 148 | 1.450 |
Why?
|
| Bronchoscopy | 4 | 2019 | 56 | 1.150 |
Why?
|
| Lung | 10 | 2019 | 235 | 1.130 |
Why?
|
| Sputum | 6 | 2019 | 33 | 1.000 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 120 | 0.960 |
Why?
|
| Cluster Analysis | 6 | 2019 | 129 | 0.900 |
Why?
|
| Bronchodilator Agents | 9 | 2019 | 82 | 0.880 |
Why?
|
| Forced Expiratory Volume | 17 | 2019 | 112 | 0.770 |
Why?
|
| Humans | 67 | 2019 | 29293 | 0.770 |
Why?
|
| Dyspnea | 2 | 2019 | 31 | 0.740 |
Why?
|
| Neutrophils | 4 | 2019 | 102 | 0.720 |
Why?
|
| Adult | 40 | 2019 | 8484 | 0.710 |
Why?
|
| Cough | 1 | 2019 | 19 | 0.700 |
Why?
|
| Eosinophils | 7 | 2019 | 48 | 0.690 |
Why?
|
| Respiratory Function Tests | 12 | 2019 | 111 | 0.690 |
Why?
|
| Male | 45 | 2019 | 17896 | 0.620 |
Why?
|
| Hypersensitivity | 2 | 2017 | 25 | 0.620 |
Why?
|
| Female | 45 | 2019 | 18270 | 0.610 |
Why?
|
| Adolescent | 23 | 2019 | 3267 | 0.610 |
Why?
|
| Immunologic Factors | 1 | 2017 | 48 | 0.590 |
Why?
|
| Immunotherapy | 1 | 2017 | 71 | 0.580 |
Why?
|
| Leukocyte Count | 3 | 2019 | 55 | 0.550 |
Why?
|
| Smoking | 1 | 2019 | 440 | 0.540 |
Why?
|
| Middle Aged | 31 | 2019 | 10892 | 0.520 |
Why?
|
| Bronchoalveolar Lavage Fluid | 5 | 2019 | 67 | 0.500 |
Why?
|
| Young Adult | 16 | 2019 | 2415 | 0.500 |
Why?
|
| Administration, Inhalation | 10 | 2019 | 92 | 0.480 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2019 | 1079 | 0.460 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2019 | 36 | 0.440 |
Why?
|
| Child | 17 | 2019 | 2226 | 0.430 |
Why?
|
| Albuterol | 5 | 2017 | 40 | 0.430 |
Why?
|
| Bronchi | 5 | 2019 | 41 | 0.410 |
Why?
|
| European Continental Ancestry Group | 9 | 2019 | 1131 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 375 | 0.360 |
Why?
|
| Alendronate | 2 | 2019 | 12 | 0.350 |
Why?
|
| Epithelial Cells | 3 | 2019 | 139 | 0.330 |
Why?
|
| Genome-Wide Association Study | 5 | 2016 | 544 | 0.330 |
Why?
|
| Nitric Oxide | 6 | 2017 | 116 | 0.320 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2019 | 50 | 0.310 |
Why?
|
| Cohort Studies | 8 | 2019 | 1697 | 0.300 |
Why?
|
| Age of Onset | 4 | 2012 | 95 | 0.290 |
Why?
|
| Glucocorticoids | 3 | 2019 | 149 | 0.290 |
Why?
|
| Immunoglobulin E | 6 | 2017 | 47 | 0.280 |
Why?
|
| Comorbidity | 5 | 2019 | 546 | 0.270 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2019 | 17 | 0.260 |
Why?
|
| Case-Control Studies | 7 | 2019 | 862 | 0.260 |
Why?
|
| Gene Expression | 2 | 2019 | 333 | 0.250 |
Why?
|
| Disease Progression | 2 | 2017 | 572 | 0.250 |
Why?
|
| Aged | 13 | 2019 | 9528 | 0.250 |
Why?
|
| Age Factors | 5 | 2017 | 1115 | 0.250 |
Why?
|
| United States | 11 | 2019 | 3655 | 0.230 |
Why?
|
| Sex Factors | 2 | 2018 | 632 | 0.210 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 9 | 0.210 |
Why?
|
| Granulocytes | 2 | 2013 | 12 | 0.210 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 725 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 299 | 0.210 |
Why?
|
| Breath Tests | 5 | 2017 | 18 | 0.200 |
Why?
|
| African Americans | 7 | 2019 | 1373 | 0.200 |
Why?
|
| Arginine | 2 | 2012 | 18 | 0.190 |
Why?
|
| Signal Transduction | 3 | 2019 | 667 | 0.190 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 49 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 156 | 0.180 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 8 | 0.180 |
Why?
|
| Influenza Vaccines | 2 | 2010 | 78 | 0.180 |
Why?
|
| Aging | 2 | 2016 | 883 | 0.170 |
Why?
|
| Double-Blind Method | 6 | 2019 | 504 | 0.170 |
Why?
|
| Respiration Disorders | 1 | 2019 | 8 | 0.170 |
Why?
|
| Glycoproteins | 1 | 2019 | 34 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 838 | 0.170 |
Why?
|
| Phosphoproteins | 1 | 2019 | 54 | 0.170 |
Why?
|
| Influenza, Human | 2 | 2010 | 122 | 0.170 |
Why?
|
| Androstadienes | 2 | 2010 | 17 | 0.170 |
Why?
|
| Perioperative Nursing | 1 | 2018 | 2 | 0.160 |
Why?
|
| Vital Capacity | 3 | 2013 | 44 | 0.160 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 28 | 0.160 |
Why?
|
| Death | 1 | 2018 | 43 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2019 | 2035 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 200 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 69 | 0.150 |
Why?
|
| Prednisolone | 1 | 2017 | 10 | 0.150 |
Why?
|
| Obesity | 3 | 2017 | 1070 | 0.150 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2016 | 9 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2017 | 36 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 49 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 481 | 0.140 |
Why?
|
| Inflammation | 2 | 2017 | 508 | 0.130 |
Why?
|
| Research | 1 | 2015 | 72 | 0.130 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 53 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2012 | 20 | 0.130 |
Why?
|
| Cytokines | 1 | 2016 | 243 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 467 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 2 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 871 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2014 | 21 | 0.120 |
Why?
|
| Respiratory Mechanics | 1 | 2013 | 8 | 0.120 |
Why?
|
| Bronchial Provocation Tests | 2 | 2011 | 14 | 0.120 |
Why?
|
| Vitamins | 1 | 2014 | 59 | 0.120 |
Why?
|
| Pneumonia | 1 | 2013 | 61 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 90 | 0.110 |
Why?
|
| Th1 Cells | 1 | 2013 | 18 | 0.110 |
Why?
|
| Skin Tests | 3 | 2010 | 15 | 0.110 |
Why?
|
| Risk Factors | 4 | 2013 | 3560 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2013 | 1170 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 638 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 13 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2013 | 333 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 50 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 37 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 12 | 0.100 |
Why?
|
| Hispanic Americans | 3 | 2014 | 904 | 0.100 |
Why?
|
| Cross-Over Studies | 3 | 2019 | 95 | 0.100 |
Why?
|
| Acetates | 1 | 2010 | 15 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 97 | 0.090 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2010 | 4 | 0.090 |
Why?
|
| Interleukin-5 | 1 | 2010 | 7 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2011 | 173 | 0.090 |
Why?
|
| Eosinophilia | 1 | 2010 | 16 | 0.090 |
Why?
|
| Th2 Cells | 1 | 2010 | 14 | 0.090 |
Why?
|
| Quinolines | 1 | 2010 | 27 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1371 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 11 | 0.090 |
Why?
|
| Infant | 1 | 2013 | 974 | 0.090 |
Why?
|
| Linkage Disequilibrium | 4 | 2012 | 192 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 30 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 25 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2011 | 131 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 35 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2011 | 256 | 0.090 |
Why?
|
| Discriminant Analysis | 1 | 2009 | 18 | 0.090 |
Why?
|
| Vitamin D | 1 | 2010 | 173 | 0.080 |
Why?
|
| Arginase | 1 | 2008 | 8 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 197 | 0.080 |
Why?
|
| Linear Models | 3 | 2018 | 427 | 0.080 |
Why?
|
| Bronchoconstriction | 1 | 2007 | 2 | 0.080 |
Why?
|
| Airway Resistance | 1 | 2007 | 5 | 0.080 |
Why?
|
| Logistic Models | 3 | 2019 | 729 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 286 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 246 | 0.080 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 25 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2017 | 868 | 0.070 |
Why?
|
| Airway Obstruction | 1 | 2006 | 31 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 196 | 0.070 |
Why?
|
| Prevalence | 2 | 2019 | 908 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 143 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 641 | 0.060 |
Why?
|
| Population Groups | 1 | 2004 | 7 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2004 | 21 | 0.060 |
Why?
|
| Ethnic Groups | 1 | 2007 | 440 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 981 | 0.060 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2015 | 22 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 11 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 143 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2014 | 159 | 0.060 |
Why?
|
| African Continental Ancestry Group | 1 | 2003 | 350 | 0.050 |
Why?
|
| Mice | 1 | 2008 | 2380 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2017 | 3116 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 3729 | 0.050 |
Why?
|
| Haplotypes | 3 | 2006 | 220 | 0.050 |
Why?
|
| Macrophages, Alveolar | 1 | 2019 | 9 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 273 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 8 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 26 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2019 | 40 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 55 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 19 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 15 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 59 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 33 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 110 | 0.040 |
Why?
|
| Quality of Life | 2 | 2016 | 824 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 249 | 0.040 |
Why?
|
| Alleles | 1 | 2019 | 251 | 0.040 |
Why?
|
| Puberty | 1 | 2018 | 8 | 0.040 |
Why?
|
| Spirometry | 2 | 2008 | 32 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 241 | 0.040 |
Why?
|
| Family | 1 | 2018 | 105 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 144 | 0.040 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 4 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 15 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2019 | 801 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 178 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2017 | 186 | 0.040 |
Why?
|
| Pediatrics | 1 | 2018 | 132 | 0.040 |
Why?
|
| Bacteria | 1 | 2016 | 45 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 16 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 293 | 0.030 |
Why?
|
| Animals | 1 | 2008 | 7318 | 0.030 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2015 | 3 | 0.030 |
Why?
|
| Education | 1 | 2015 | 30 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 114 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 150 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 436 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 160 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 493 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 448 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 169 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 386 | 0.030 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 5 | 0.030 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 16 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2013 | 26 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 149 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2011 | 5 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2011 | 95 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3129 | 0.030 |
Why?
|
| Thrombospondins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 225 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 47 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 16 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 4 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 29 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2010 | 8 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 418 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 66 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 72 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 90 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2011 | 87 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 16 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 735 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 152 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 125 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 101 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1366 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 21 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2007 | 3 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2007 | 5 | 0.020 |
Why?
|
| London | 1 | 2007 | 3 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2007 | 5 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 87 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 173 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 242 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 35 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 139 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 2009 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2006 | 251 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 520 | 0.020 |
Why?
|
| Netherlands | 1 | 2003 | 21 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 225 | 0.010 |
Why?
|